An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF‐mutant advanced melanoma treated with first‐line anti‐PD‐1 monotherapies or BRAF/MEK inhibitors in a community‐based oncology setting

INTRODUCTION: Anti‐PD‐1 monotherapies (aPD‐1) and BRAF/MEK inhibitors (BRAF/MEKi) changed the BRAF‐mutant advanced melanoma treatment landscape. This study aimed to improve the understanding of real‐world treatment patterns and optimal treatment sequence. METHODS: This was a retrospective study of B...

Descripción completa

Detalles Bibliográficos
Autores principales: Cowey, Charles L., Boyd, Marley, Aguilar, Kathleen M., Beeks, April, Krepler, Clemens, Scherrer, Emilie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643646/
https://www.ncbi.nlm.nih.gov/pubmed/32871054
http://dx.doi.org/10.1002/cam4.3312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643646/
https://www.ncbi.nlm.nih.gov/pubmed/32871054
http://dx.doi.org/10.1002/cam4.3312

Ejemplares similares